

# SAFETY DATA SHEET



## Ezetimibe / Rosuvastatin Formulation



Version 3.1      Revision Date: 30.09.2023      SDS Number: 3177572-00013      Date of last issue: 04.04.2023  
Date of first issue: 18.09.2018

---

### SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Ezetimibe / Rosuvastatin Formulation

#### Manufacturer or supplier's details

Company : Organon & Co.

Address : Rua Treze de Maio, 1161  
Campinas, São Paulo, Brazil 13106-054

Telephone : +55 (19) 3758-2000

Emergency telephone : +55 (11) 3173-4931

E-mail address : EHSSTEWARD@organon.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

---

### SECTION 2. HAZARDS IDENTIFICATION

#### GHS Classification in accordance with ABNT NBR 14725 Standard

Skin irritation : Category 3

Carcinogenicity : Category 1B

Reproductive toxicity : Category 1B

Specific target organ toxicity - single exposure (Oral) : Category 2 (Liver, Kidney, muscle)

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Eye)

Long-term (chronic) aquatic hazard : Category 2

#### GHS label elements in accordance with ABNT NBR 14725 Standard

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H316 Causes mild skin irritation.  
H350 May cause cancer.

## Ezetimibe / Rosuvastatin Formulation

Version 3.1      Revision Date: 30.09.2023      SDS Number: 3177572-00013      Date of last issue: 04.04.2023  
Date of first issue: 18.09.2018

H360FD May damage fertility. May damage the unborn child.  
H371 May cause damage to organs (Liver, Kidney, muscle) if swallowed.  
H373 May cause damage to organs (Eye) through prolonged or repeated exposure if swallowed.  
H411 Toxic to aquatic life with long lasting effects.

## Precautionary Statements

:

**Prevention:**

P201 Obtain special instructions before use.  
P260 Do not breathe dust.  
P273 Avoid release to the environment.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**

P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor.  
P391 Collect spillage.

**Other hazards which do not result in classification**

Dust contact with the eyes can lead to mechanical irritation.  
May form explosive dust-air mixture during processing, handling or other means.

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Classification	Concentration (% w/w)
Cellulose	9004-34-6		>= 10 -< 20
Ezetimibe	163222-33-1	Long-term (chronic) aquatic hazard, Category 1	>= 5 -< 10
Rosuvastatin	147098-20-2	Acute toxicity (Oral), Category 5 Carcinogenicity, Category 1B Reproductive toxicity, Category 1B Specific target organ toxicity - single exposure (Oral) (Liver, Kidney, muscle), Category 1 Specific target organ toxicity - repeated exposure (Oral) (Eye), Category 1 Short-term (acute) aquatic hazard, Category 3 Long-term (chronic) aquatic hazard,	>= 2,5 -< 5

# SAFETY DATA SHEET



## Ezetimibe / Rosuvastatin Formulation



Version 3.1      Revision Date: 30.09.2023      SDS Number: 3177572-00013      Date of last issue: 04.04.2023  
Date of first issue: 18.09.2018

		Category 1	
Sodium n-dodecyl sulfate	151-21-3	Acute toxicity (Oral), Category 4 Skin irritation, Category 2 Serious eye damage, Category 1 Short-term (acute) aquatic hazard, Category 2 Long-term (chronic) aquatic hazard, Category 3	$\geq 1 - < 2,5$
Magnesium stearate	557-04-0		$\geq 1 - < 5$

### SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : If in eyes, rinse well with water.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.  
Never give anything by mouth to an unconscious person.
- Most important symptoms and effects, both acute and delayed : Causes mild skin irritation.  
May cause cancer.  
May damage fertility. May damage the unborn child.  
May cause damage to organs if swallowed.  
May cause damage to organs through prolonged or repeated exposure if swallowed.
- Protection of first-aiders : Dust contact with the eyes can lead to mechanical irritation.  
First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.

### SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)

## Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	3177572-00013	Date of first issue: 18.09.2018

---

Unsuitable extinguishing media	:	Dry chemical None known.
Specific hazards during fire fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides Fluorine compounds Nitrogen oxides (NO <sub>x</sub> ) Sulfur oxides Metal oxides
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

---

**SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protective equipment and emergency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

---

**SECTION 7. HANDLING AND STORAGE**

Technical measures	:	Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding
--------------------	---	---

## Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	3177572-00013	Date of first issue: 18.09.2018

- and bonding, or inert atmospheres.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing.  
Do not breathe dust.  
Do not swallow.  
Avoid contact with eyes.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Keep container tightly closed.  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Do not eat, drink or smoke when using this product.  
Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
- Conditions for safe storage : Keep in properly labeled containers.  
Store locked up.  
Keep tightly closed.  
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents  
Self-reactive substances and mixtures  
Organic peroxides  
Explosives  
Gases

## SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	TWA	10 mg/m <sup>3</sup>	ACGIH
Ezetimibe	163222-33-1	TWA	25 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	250 µg/100 cm <sup>2</sup>	Internal
Rosuvastatin	147098-20-2	TWA	20 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	200 µg/100 cm <sup>2</sup>	Internal
Magnesium stearate	557-04-0	TWA (Inhalable)	10 mg/m <sup>3</sup>	ACGIH

# SAFETY DATA SHEET



## Ezetimibe / Rosuvastatin Formulation



Version 3.1      Revision Date: 30.09.2023      SDS Number: 3177572-00013      Date of last issue: 04.04.2023  
Date of first issue: 18.09.2018

		particulate matter)		
		TWA (Respirable particulate matter)	3 mg/m <sup>3</sup>	ACGIH

**Engineering measures** : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
Minimize open handling.

### Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

## SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Color : white to off-white

Odor : No data available

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

# SAFETY DATA SHEET



## Ezetimibe / Rosuvastatin Formulation



Version 3.1      Revision Date: 30.09.2023      SDS Number: 3177572-00013      Date of last issue: 04.04.2023  
Date of first issue: 18.09.2018

---

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : Not applicable

Relative vapor density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)  
Water solubility : No data available

Partition coefficient: n-octanol/water : Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity  
Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

---

### SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.  
Can react with strong oxidizing agents.

## Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	3177572-00013	Date of first issue: 18.09.2018

---

Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

---

**SECTION 11. TOXICOLOGICAL INFORMATION**

Information on likely routes of exposure :

- Inhalation
- Skin contact
- Ingestion
- Eye contact

**Acute toxicity**

Not classified based on available information.

**Product:**

Acute oral toxicity : Acute toxicity estimate: > 5.000 mg/kg  
Method: Calculation method

**Components:****Cellulose:**

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5,8 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg

**Ezetimibe:**

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg  
LD50 (Mouse): > 5.000 mg/kg  
LD50 (Dog): > 3.000 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of administration) : LD50 (Rat): > 2.000 mg/kg  
Application Route: Intraperitoneal  
LD50 (Mouse): > 1.000 - < 2.000 mg/kg  
Application Route: Intraperitoneal

**Rosuvastatin:**

Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg  
Target Organs: Liver, Stomach, muscle, Kidney

**Sodium n-dodecyl sulfate:**



# SAFETY DATA SHEET



## Ezetimibe / Rosuvastatin Formulation



Version 3.1      Revision Date: 30.09.2023      SDS Number: 3177572-00013      Date of last issue: 04.04.2023  
Date of first issue: 18.09.2018

---

Acute oral toxicity : LD50 (Rat): 1.200 mg/kg  
Method: OECD Test Guideline 401

Acute dermal toxicity : LD50 (Rat): > 2.000 mg/kg  
Method: OECD Test Guideline 402  
Remarks: Based on data from similar materials

### **Magnesium stearate:**

Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg  
Method: OECD Test Guideline 423  
Assessment: The substance or mixture has no acute oral toxicity  
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg  
Remarks: Based on data from similar materials

### **Skin corrosion/irritation**

Causes mild skin irritation.

### **Components:**

#### **Ezetimibe:**

Species : Rabbit  
Result : No skin irritation

#### **Sodium n-dodecyl sulfate:**

Species : Rabbit  
Result : Skin irritation

#### **Magnesium stearate:**

Species : Rabbit  
Result : No skin irritation  
Remarks : Based on data from similar materials

### **Serious eye damage/eye irritation**

Not classified based on available information.

### **Components:**

#### **Ezetimibe:**

Species : Rabbit  
Result : No eye irritation

#### **Sodium n-dodecyl sulfate:**

Species : Rabbit  
Result : Irreversible effects on the eye  
Method : OECD Test Guideline 405

#### **Magnesium stearate:**

Species : Rabbit

## Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	3177572-00013	Date of first issue: 18.09.2018

---

Result : No eye irritation  
Remarks : Based on data from similar materials

**Respiratory or skin sensitization****Skin sensitization**

Not classified based on available information.

**Respiratory sensitization**

Not classified based on available information.

**Components:****Ezetimibe:**

Test Type : Maximization Test  
Species : Guinea pig  
Result : negative

**Sodium n-dodecyl sulfate:**

Test Type : Maximization Test  
Routes of exposure : Skin contact  
Species : Guinea pig  
Result : negative  
Remarks : Based on data from similar materials

**Magnesium stearate:**

Test Type : Maximization Test  
Routes of exposure : Skin contact  
Species : Guinea pig  
Method : OECD Test Guideline 406  
Result : negative  
Remarks : Based on data from similar materials

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Cellulose:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Result: negative

**Ezetimibe:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

## Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	3177572-00013	Date of first issue: 18.09.2018

---

Metabolic activation: with and without metabolic activation  
Result: negative

Test Type: Chromosomal aberration  
Test system: Human lymphocytes  
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Mouse  
Cell type: Bone marrow  
Application Route: Oral  
Result: negative

**Rosuvastatin:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Test system: Escherichia coli  
Result: negative

Test Type: Chromosomal aberration  
Test system: Chinese hamster lung cells  
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Mouse  
Cell type: Bone marrow  
Application Route: Ingestion  
Result: negative

**Sodium n-dodecyl sulfate:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Method: OECD Test Guideline 471  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Genotoxicity in vivo : Test Type: Rodent dominant lethal test (germ cell) (in vivo)  
Species: Mouse  
Application Route: Ingestion  
Result: negative

**Magnesium stearate:**

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

## Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	3177572-00013	Date of first issue: 18.09.2018

---

Remarks: Based on data from similar materials

**Carcinogenicity**

May cause cancer.

**Components:****Cellulose:**

Species	:	Rat
Application Route	:	Ingestion
Exposure time	:	72 weeks
Result	:	negative

**Ezetimibe:**

Species	:	Rat, female
Application Route	:	oral (feed)
Exposure time	:	104 weeks
Result	:	negative

Species	:	Rat, male
Application Route	:	oral (feed)
Exposure time	:	104 weeks
Result	:	negative

Species	:	Mouse
Application Route	:	oral (feed)
Exposure time	:	104 weeks
Result	:	negative

**Rosuvastatin:**

Species	:	Rat
Application Route	:	Oral
Exposure time	:	104 weeks
LOAEL	:	80 mg/kg body weight
Result	:	positive
Symptoms	:	Tumor
Target Organs	:	Uterus (including cervix)

Species	:	Mouse
Application Route	:	Oral
Exposure time	:	107 weeks
LOAEL	:	200 mg/kg body weight
Result	:	positive
Symptoms	:	liver adenoma, carcinoma
Target Organs	:	Liver

**Sodium n-dodecyl sulfate:**

Species	:	Rat
Application Route	:	Ingestion
Exposure time	:	2 Years
Method	:	OECD Test Guideline 453
Result	:	negative

## Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	3177572-00013	Date of first issue: 18.09.2018

---

Remarks : Based on data from similar materials

**Reproductive toxicity**

May damage fertility. May damage the unborn child.

**Components:****Cellulose:**

Effects on fertility : Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Result: negative

**Ezetimibe:**

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat, male and female  
Fertility: NOAEL: > 1.000 mg/kg body weight  
Result: No effects on fertility., No fetotoxicity.

Effects on fetal development : Test Type: Development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: > 1.000 mg/kg body weight  
Result: No adverse effects.

Test Type: Development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: NOAEL: > 1.000 mg/kg body weight  
Result: No adverse effects.

**Rosuvastatin:**

Effects on fertility : Test Type: Fertility  
Species: Rat  
Application Route: Oral  
Fertility: NOAEL: 50 mg/kg body weight

Test Type: Fertility  
Species: Monkey  
Application Route: Oral  
Fertility: LOAEL: 30 mg/kg body weight  
Result: Effects on male and female reproductive organs.

Effects on fetal development : Test Type: Development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: LOAEL: 50 mg/kg body weight  
Result: Fetal mortality.

## Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	3177572-00013	Date of first issue: 18.09.2018

---

Test Type: Development  
 Species: Rabbit  
 Application Route: Oral  
 Developmental Toxicity: LOAEL: 3 mg/kg body weight  
 Result: Fetal mortality., Maternal toxicity observed.

Reproductive toxicity - Assessment : May damage fertility. May damage the unborn child.

**Sodium n-dodecyl sulfate:**

Effects on fertility : Test Type: Two-generation reproduction toxicity study  
 Species: Rat  
 Application Route: Ingestion  
 Method: OECD Test Guideline 416  
 Result: negative  
 Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development  
 Species: Rat  
 Application Route: Ingestion  
 Result: negative  
 Remarks: Based on data from similar materials

**Magnesium stearate:**

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test  
 Species: Rat  
 Application Route: Ingestion  
 Method: OECD Test Guideline 422  
 Result: negative  
 Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development  
 Species: Rat  
 Application Route: Ingestion  
 Result: negative  
 Remarks: Based on data from similar materials

**STOT-single exposure**

May cause damage to organs (Liver, Kidney, muscle) if swallowed.

**Components:****Rosuvastatin:**

Routes of exposure : Oral  
 Target Organs : Liver, Kidney, muscle  
 Assessment : Causes damage to organs.

**STOT-repeated exposure**

May cause damage to organs (Eye) through prolonged or repeated exposure if swallowed.

## Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	3177572-00013	Date of first issue: 18.09.2018

---

**Components:****Rosuvastatin:**

Routes of exposure	:	Oral
Target Organs	:	Eye
Assessment	:	Causes damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****Cellulose:**

Species	:	Rat
NOAEL	:	>= 9.000 mg/kg
Application Route	:	Ingestion
Exposure time	:	90 Days

**Ezetimibe:**

Species	:	Dog
NOAEL	:	1.000 mg/kg
Application Route	:	Oral
Exposure time	:	90 d
Remarks	:	No significant adverse effects were reported

Species	:	Rat
NOAEL	:	1.500 mg/kg
Application Route	:	Oral
Exposure time	:	90 d
Remarks	:	No significant adverse effects were reported

Species	:	Mouse
NOAEL	:	500 mg/kg
Application Route	:	Oral
Exposure time	:	90 d
Remarks	:	No significant adverse effects were reported

Species	:	Dog
NOAEL	:	300 mg/kg
Application Route	:	Oral
Exposure time	:	1 y
Remarks	:	No significant adverse effects were reported

**Rosuvastatin:**

Species	:	Dog
LOAEL	:	90 mg/kg
Application Route	:	Oral
Exposure time	:	24 Days
Target Organs	:	Brain
Symptoms	:	Edema, Blood disorders, Necrosis
Remarks	:	Based on data from similar materials

Species	:	Dog
---------	---	-----

## Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	3177572-00013	Date of first issue: 18.09.2018

---

LOAEL : 6 mg/kg  
 Application Route : Oral  
 Exposure time : 52 Weeks  
 Target Organs : Cornea  
 Symptoms : Corneal opacity  
 Remarks : Based on data from similar materials

Species : Dog  
 LOAEL : 30 mg/kg  
 Application Route : Oral  
 Exposure time : 12 Weeks  
 Target Organs : Eye  
 Symptoms : Eye disease  
 Remarks : Based on data from similar materials

Species : Dog  
 LOAEL : 90 mg/kg  
 Application Route : Oral  
 Exposure time : 4 Weeks  
 Target Organs : eye - retina  
 Symptoms : Eye disease  
 Remarks : Based on data from similar materials

**Sodium n-dodecyl sulfate:**

Species : Rat  
 NOAEL : 488 mg/kg  
 Application Route : Ingestion  
 Exposure time : 90 Days  
 Remarks : Based on data from similar materials

**Magnesium stearate:**

Species : Rat  
 NOAEL : > 100 mg/kg  
 Application Route : Ingestion  
 Exposure time : 90 Days  
 Remarks : Based on data from similar materials

**Aspiration toxicity**

Not classified based on available information.

**Components:****Ezetimibe:**

Not applicable

**Experience with human exposure****Components:****Ezetimibe:**

Ingestion : Symptoms: Headache, Nausea, Vomiting, Diarrhea, flatulence, muscle pain, upper respiratory tract infection, Back pain, joint pain



## Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	3177572-00013	Date of first issue: 18.09.2018

---

**Rosuvastatin:**

Ingestion : Target Organs: Kidney  
Symptoms: kidney toxicity  
Remarks: Based on Human Evidence  
Target Organs: muscle  
Symptoms: musculoskeletal pain  
Remarks: Based on Human Evidence  
Target Organs: Liver  
Symptoms: liver function change  
Remarks: Based on Human Evidence

---

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****Cellulose:**

Toxicity to fish : LC50 (*Oryzias latipes* (Japanese medaka)): > 100 mg/l  
Exposure time: 48 h  
Remarks: Based on data from similar materials

**Ezetimibe:**

Toxicity to fish : LC50 (*Pimephales promelas* (fathead minnow)): > 0,125 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203  
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates : EC50 (*Daphnia magna* (Water flea)): > 4 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202  
Remarks: No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants : EC50 (*Pseudokirchneriella subcapitata* (green algae)): > 0,317 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 201  
Remarks: No toxicity at the limit of solubility.

NOEC (*Pseudokirchneriella subcapitata* (green algae)): 0,317 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 201  
Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic toxicity) : NOEC (*Pimephales promelas* (fathead minnow)): 0,051 mg/l  
Exposure time: 33 d  
Method: OECD Test Guideline 210

NOEC (*Cyprinodon variegatus* (sheepshead minnow)): 4 mg/l  
Exposure time: 7 d  
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other : NOEC (*Daphnia magna* (Water flea)): 0,282 mg/l

## Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	3177572-00013	Date of first issue: 18.09.2018

---

aquatic invertebrates (Chronic toxicity) : Exposure time: 21 d  
Remarks: No toxicity at the limit of solubility.

M-Factor (Chronic aquatic toxicity) : 1

Toxicity to microorganisms : EC50: > 4,4 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209  
Remarks: No toxicity at the limit of solubility.

NOEC: 4,4 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209  
Remarks: No toxicity at the limit of solubility.

**Rosuvastatin:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 1.000 mg/l  
Exposure time: 96 hrs  
Method: FDA 4.11

LC50 (Lepomis macrochirus (Bluegill sunfish)): > 1.000 mg/l  
Exposure time: 96 hrs  
Method: FDA 4.11

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 63 mg/l  
Exposure time: 48 hrs  
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Microcystis aeruginosa (blue-green algae)): > 640 mg/l  
Exposure time: 96 hrs  
Method: FDA 4.01

NOEC (Microcystis aeruginosa (blue-green algae)): 330 mg/l  
Exposure time: 96 hrs  
Method: FDA 4.01

EC50 (Pseudokirchneriella subcapitata (green algae)): > 800 mg/l  
Exposure time: 96 hrs  
Method: FDA 4.01

NOEC (Pseudokirchneriella subcapitata (green algae)): 350 mg/l  
Exposure time: 96 hrs  
Method: FDA 4.01

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 1 mg/l  
Exposure time: 32 Days  
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic) : NOEC (Daphnia magna (Water flea)): 0,018 mg/l  
Exposure time: 21 Days

## Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	3177572-00013	Date of first issue: 18.09.2018

---

ic toxicity) Method: OECD Test Guideline 211

M-Factor (Chronic aquatic toxicity) : 1

Toxicity to microorganisms : EC50: > 100 mg/l  
Exposure time: 3 hrs  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

NOEC: 100 mg/l  
Exposure time: 3 hrs  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

**Sodium n-dodecyl sulfate:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 29 mg/l  
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Ceriodaphnia dubia (water flea)): 5,55 mg/l  
Exposure time: 48 h

Toxicity to algae/aquatic plants : ErC50 (Desmodesmus subspicatus (green algae)): > 120 mg/l  
Exposure time: 72 h

NOEC (Desmodesmus subspicatus (green algae)): 30 mg/l  
Exposure time: 72 h

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): >= 1,357 mg/l  
Exposure time: 42 d

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Ceriodaphnia dubia (water flea)): 0,88 mg/l  
Exposure time: 7 d

Toxicity to microorganisms : EC50: 135 mg/l  
Exposure time: 3 h

**Magnesium stearate:**

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l  
Exposure time: 48 h  
Method: DIN 38412  
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l  
Exposure time: 47 h  
Test substance: Water Accommodated Fraction  
Method: Directive 67/548/EEC, Annex V, C.2.  
Remarks: Based on data from similar materials  
No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l  
Exposure time: 72 h  
Test substance: Water Accommodated Fraction

## Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	3177572-00013	Date of first issue: 18.09.2018

---

Method: OECD Test Guideline 201  
 Remarks: Based on data from similar materials  
 No toxicity at the limit of solubility.

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l

Exposure time: 72 h  
 Test substance: Water Accommodated Fraction  
 Method: OECD Test Guideline 201  
 Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l  
 Exposure time: 16 h  
 Test substance: Water Accommodated Fraction  
 Remarks: Based on data from similar materials

**Persistence and degradability****Components:****Cellulose:**

Biodegradability : Result: Readily biodegradable.

**Ezetimibe:**

Biodegradability : Result: Not readily biodegradable.  
 Biodegradation: 6,8 %  
 Exposure time: 28 d

Stability in water : Hydrolysis: 50 %(4,5 d)  
 Method: OECD Test Guideline 111

**Rosuvastatin:**

Biodegradability : Biodegradation: < 10 %  
 Exposure time: 28 Days  
 Method: OECD Test Guideline 301F  
 Remarks: Not inherently biodegradable.

Stability in water : Hydrolysis: < 10 %(5 Days)

**Sodium n-dodecyl sulfate:**

Biodegradability : Result: Readily biodegradable.  
 Biodegradation: 95 %  
 Exposure time: 28 d  
 Method: OECD Test Guideline 301B

**Magnesium stearate:**

Biodegradability : Result: Not biodegradable  
 Remarks: Based on data from similar materials

## Ezetimibe / Rosuvastatin Formulation

Version 3.1      Revision Date: 30.09.2023      SDS Number: 3177572-00013      Date of last issue: 04.04.2023  
Date of first issue: 18.09.2018

---

**Bioaccumulative potential****Components:****Ezetimibe:**

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)  
Bioconcentration factor (BCF): 173  
Exposure time: 97 d  
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4,36

**Rosuvastatin:**

Partition coefficient: n-octanol/water : log Pow: 0,3

**Sodium n-dodecyl sulfate:**

Partition coefficient: n-octanol/water : log Pow: 0,83

**Magnesium stearate:**

Partition coefficient: n-octanol/water : log Pow: > 4

**Mobility in soil****Components:****Ezetimibe:**

Distribution among environmental compartments : log Koc: 4,35  
Method: OECD Test Guideline 106

**Rosuvastatin:**

Distribution among environmental compartments : log Koc: 2,15  
Method: FDA 3.08

**Other adverse effects**

No data available

---

**SECTION 13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.  
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**



# SAFETY DATA SHEET



## Ezetimibe / Rosuvastatin Formulation



Version            Revision Date:            SDS Number:            Date of last issue: 04.04.2023  
3.1                30.09.2023                3177572-00013            Date of first issue: 18.09.2018

---

### SECTION 15. REGULATORY INFORMATION

#### Safety, health and environmental regulations/legislation specific for the substance or mixture

National List of Carcinogenic Agents for Humans - (LINACH) : Not applicable

Brazil. List of chemicals controlled by the Federal Police : Not applicable

#### The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

---

### SECTION 16. OTHER INFORMATION

Revision Date : 30.09.2023  
Date format : dd.mm.yyyy

#### Further information

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

#### Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AllC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECl - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect

# SAFETY DATA SHEET



## Ezetimibe / Rosuvastatin Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	3177572-00013	Date of first issue: 18.09.2018

---

Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECl - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

BR / Z8